Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol 2022 Sep 01;23(9)1133-1144, T Powles, P Tomczak, SH Park, B Venugopal, T Ferguson, SN Symeonides, J Hajek, H Gurney, YH Chang, JL Lee, N Sarwar, A Thiery-Vuillemin, M Gross-Goupil, M Mahave, NB Haas, P Sawrycki, JE Burgents, L Xu, K Imai, DI Quinn, TK Choueiri
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.